Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

National survey highlights need for greater awareness on lymphoma

While general awareness of lymphoma remains high, a new survey released today by the Lymphoma Research Foundation (LRF) reveals significant knowledge gaps among Americans about the disease, which is the most prevalent form of blood cancer in the United States. Survey results showed a high number of adults (86 percent) remain unaware that there are 67 different types of lymphoma - 61 types of non-Hodgkin lymphoma and six types of Hodgkin lymphoma.

21 Sep 2010

Pollution increases risk for sudden cardiac arrest

The fine particles of pollution that hang in the air can increase the risk for sudden cardiac arrest, according to a new study conducted by a team from Long Island Jewish (LIJ) Medical Center and The Feinstein Institute for Medical Research.

21 Sep 2010

Micromet initiates MT103 phase 2 trial in adult ALL patients

Micromet, Inc. today announced the initiation of a phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is the first of a new class of agents called BiTE antibodies, designed to harness the body's T cells to kill cancer cells.

20 Sep 2010

Immunotherapy accepted for coverage in MEDLINE®

Future Medicine Ltd announced today that its journal Immunotherapy (ISSN 1750-743X) has been selected for coverage in MEDLINE®. Maintained by the U.S. National Library of Medicine, MEDLINE® (Medical Literature Analysis and Retrieval System Online) is a premier bibliographic database containing approximately 13 million references to journal articles in life sciences.

19 Sep 2010

The John Theurer Cancer Center to host Second Annual Celebrating Life and Liberty cancer survivor event

The John Theurer Cancer Center at Hackensack University Medical Center announced that thousands of cancer survivors and caregivers will celebrate life, liberty and new beginnings with the ultimate symbol of freedom close by the Statue of Liberty.

18 Sep 2010

Scientists discover protein to regulate blood stem cells’ activity for leukemia treatment

A discovery made by Dr. Tarik Möröy, President and Scientific Director and Director of the IRCM, and his team was recently published in Blood, the official journal of the American Society of Hematology. The researchers found that a protein can regulate certain characteristics of blood stem cells, which could lead to a better treatment for leukemia patients.

17 Sep 2010

BioCryst Pharmaceuticals announces BCX4208 compound results for treating gout

BioCryst Pharmaceuticals, Inc. announced positive top-line results from its randomized, double-blind, multi-center, placebo-controlled Phase 2 study designed to evaluate the urate-lowering activity and safety of several doses of BCX4208 alone and in combination with selected doses of allopurinol administered once-daily.

16 Sep 2010

BioCryst reports results from forodesine studies for CTCL and CLL

BioCryst Pharmaceuticals, Inc. announced preliminary top-line results from its multinational, open-label, single-arm trial evaluating 200 mg once-daily oral forodesine in the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL), as well as interim results from the Company's exploratory Phase 2 study to investigate the efficacy and safety of 200 mg twice-daily oral forodesine as monotherapy for chronic lymphocytic leukemia (CLL).

15 Sep 2010

Apricus Biosciences announces reformulation of Rituxan enables rectal delivery of biologics

Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT drug delivery technology and internal pipeline through out-licensing arrangements and partnerships, today announced results from a pre-clinical pharmacokinetic study showing the ability of NexACT to enable rectal delivery of biologics, such as human antibodies.

15 Sep 2010

CSC launches new educational program to enhance lymphoma patient, physician communication

The Cancer Support Community (CSC), uniting The Wellness Community and Gilda's Club Worldwide, announced today the launch of Framing Life With Lymphoma, a new educational program designed to enhance lymphoma patient and physician communication.

14 Sep 2010

Data from Phase II trial of zanolimumab in PTCL published in British Journal of Haematology

TenX Biopharma, Inc. announced today that data from a Phase II trial of zanolimumab (HuMax-CD4®) in peripheral T-cell Lymphoma were published in the British Journal of Haematology (Sep 2010: 150(5):565-73). The Hx-CD4-109 trial was designed to evaluate the safety and efficacy of zanolimumab in patients who have relapsed or refractory non-cutaneous peripheral T-cell lymphoma.

14 Sep 2010

Stars join Bupa 30th Great North Run for Leukaemia & Lymphoma Research

Soap stars warm up for Bupa 30th Great North Run for Leukaemia & Lymphoma Research

14 Sep 2010

Gilead Sciences announces Quad regimen Phase II clinical trial results for HIV infection treatment

Gilead Sciences, Inc. today announced Phase II clinical trial results showing that its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat and Truvada (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection maintained a high rate of virologic suppression through 48 weeks, exhibiting antiretroviral activity comparable to that of Atripla(efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).

14 Sep 2010

$Cell Therapeutics to appeal FDA decision on pixantrone NDA for relapsed/refractory aggressive NHL$

Cell Therapeutics to appeal FDA decision on pixantrone NDA for relapsed/refractory aggressive NHL

Cell Therapeutics, Inc. today announced that it intends to appeal the U.S. Food and Drug Administration's previously disclosed decision regarding the pixantrone New Drug Application ("NDA") to treat patients with relapsed/refractory aggressive non-Hodgkin's lymphoma ("NHL").

14 Sep 2010

OSUCCC-James researchers identify experimental agent that targets chronic lymphocytic leukemia

Researchers at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) have identified an experimental agent that targets chronic lymphocytic leukemia and perhaps other proliferative disorders of lymphocytes.

14 Sep 2010

Arno Therapeutics closes private placement to advance cancer treatment

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced that it has closed a private placement of its securities resulting in gross proceeds to the company of over $15 million.

14 Sep 2010

Pharmacyclics reports $9.3 million increase in total revenue for 2010 fiscal year

Pharmacyclics, Inc. today reported financial results for its fiscal year and fourth quarter which ended June 30, 2010.

14 Sep 2010

Genoptix to participate 2010 UBS Global Life Sciences Conference

Genoptix, Inc., a specialized laboratory services provider, today announced the Company's participation at the 2010 UBS Global Life Sciences Conference at the Grand Hyatt Hotel in New York City, to be held September 20-22, 2010.

13 Sep 2010

Cyclacel reaches SPA agreement with FDA for sapacitabine Phase 3 trial in AML

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.

13 Sep 2010

Seattle Genetics' lintuzumab phase IIb clinical trial for AML does not meet primary endpoint

Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.

13 Sep 2010

Lymphoma News and Research

Further Reading

National survey highlights need for greater awareness on lymphoma

Pollution increases risk for sudden cardiac arrest

Micromet initiates MT103 phase 2 trial in adult ALL patients

Immunotherapy accepted for coverage in MEDLINE®

The John Theurer Cancer Center to host Second Annual Celebrating Life and Liberty cancer survivor event

Scientists discover protein to regulate blood stem cells’ activity for leukemia treatment

BioCryst Pharmaceuticals announces BCX4208 compound results for treating gout

BioCryst reports results from forodesine studies for CTCL and CLL

Apricus Biosciences announces reformulation of Rituxan enables rectal delivery of biologics

CSC launches new educational program to enhance lymphoma patient, physician communication

Data from Phase II trial of zanolimumab in PTCL published in British Journal of Haematology

Stars join Bupa 30th Great North Run for Leukaemia & Lymphoma Research

Gilead Sciences announces Quad regimen Phase II clinical trial results for HIV infection treatment

Cell Therapeutics to appeal FDA decision on pixantrone NDA for relapsed/refractory aggressive NHL

OSUCCC-James researchers identify experimental agent that targets chronic lymphocytic leukemia

Arno Therapeutics closes private placement to advance cancer treatment

Pharmacyclics reports $9.3 million increase in total revenue for 2010 fiscal year

Genoptix to participate 2010 UBS Global Life Sciences Conference

Cyclacel reaches SPA agreement with FDA for sapacitabine Phase 3 trial in AML

Seattle Genetics' lintuzumab phase IIb clinical trial for AML does not meet primary endpoint

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News